ZEALAND PHARMA A/S: Financial statements 2023
CVR: 20045078
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
ZEALAND PHARMA A/S (CVR 20045078) has filed annual accounts for 2023. In 2023, the company reported revenue of DKK 342,788,000 and a net result of DKK -703,739,000 compared with EUR -1,202,135,000 the year before. That is an increase of 229.6% compared with the year before. The profit margin was -205.3%. Equity in the 2023 report amounted to DKK 1,592,839,000. The solvency ratio was 80.4%. The company had 235 employees in the financial year.
- Revenue
- DKK 342,788,000
- Gross Profit
- DKK 323,614,000
- Profit/Loss
- DKK -703,739,000
- Equity
- DKK 1,592,839,000
- Total Assets
- DKK 1,979,993,000
- Employees
- 235
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | 342.8M | 323.6M | -703.7M | 1.6B | 235 |
| 2022 | 104M EUR | 104M EUR | -1.2B EUR | 815.9M EUR | 247 |
| 2021 | 292.6M | 173.8M | -1B | 927.8M | 346 |
| 2020 | 353.3M | 262.7M | -846.7M | 1.2B | 297 |
| 2019 | 41.3M | - | -571.5M | 1.2B | - |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
ZEALAND PHARMA A/S has published its interim report for the period January 1, 2023 to September 30, 2023.
As of October 19, 2023, is registered as an owner of ZEALAND PHARMA A/S with an ownership share of 5%.
ZEALAND PHARMA A/S has published its interim report for the period January 1, 2023 to June 30, 2023.
ZEALAND PHARMA A/S has published its interim report for the period January 1, 2023 to March 31, 2023.
ZEALAND PHARMA A/S has published its annual report for 2022. Revenue came to DKK 103,986,000, and the net result was DKK -1,202,135,000.
About ZEALAND PHARMA A/S
ZEALAND PHARMA A/S is a Danish company of the type Aktieselskab based in Søborg, founded in 1997. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named ZEALAND PHARMACEUTICALS A/S and PEPTIDE PROBE TECHNOLOGIES ApS. The management consists of Adam Sinding Steensberg and Henriette Wennicke. The board consists of Alf Gunnar Martin Nicklasson (chair), Kirsten Aarup Drejer, Adam Krisko Nygaard and Anneline Nansen. The company's owners include ZEALAND PHARMA A/S, Van Herk Investments B.V. and Van Herk Management Services B.V.. The company has 575 employees (2026). In 2025, the company reported revenue of DKK 9,214,860,000 and a net result of DKK 6,455,008,000 compared with DKK -1,078,828,000 the year before. Equity in the 2025 report amounted to DKK 14,830,613,000.
